tradmap

MGTX Meiragtx Holdings Plc

$11.31 +8.85%

Healthcare · Biological Products, (No Diagnostic Substances)

Meiragtx Holdings Plc (MGTX) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $1.0 billion. Shares last traded at $11.31, 4.3% below their 52-week high. Over the past year the stock is up 79.0%. Net profit margin is -140.3%, below the peer median of 6.3%. Revenue grew 144.6% year over year.

Market Cap
$1.0B
Shares Out
92.6M
EPS (TTM)
$-3.68
P/E Ratio
P/S Ratio
12.87
P/B Ratio
Dividend / Share
Dividend Yield
52-Week High
$11.82
52-Week Low
$6.06
Volume
214,716
Avg Vol (3m)
59,135.397

Performance

1W
+17.94%
1M
+23.74%
3M
+53.88%
6M
+31.74%
YTD
+45.00%
1Y
+78.96%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
69.22
SMA (50)
$9.69
SMA (200)
$8.41
Price vs SMA50
+16.72%
Price vs SMA200
+34.50%
ATR (14)
$0.77

Financials

Revenue
$81M
Net Income
$-114M
Gross Margin
Operating Margin
-130.2%
Net Margin
-140.3%
Return on Equity
196.5%
Return on Assets
-46.7%
Current Ratio
0.55
Debt / Equity
-5.21
Revenue Growth (YoY)
+144.6%

Latest reported annual period ending 2025-12-31 · SEC EDGAR/XBRL.

Recent earnings

PeriodEPS (diluted)Reported
Q1 2026 $-0.57 2026-05-14
FY 2025 $-1.42 2026-03-30
Q3 2025 $-1.61 2025-11-13
Q2 2025 $-0.99 2025-08-14
Q1 2026 $-0.51 2026-05-14
FY 2025 $-2.12 2026-03-30

Full earnings history →

Biological Products, (No Diagnostic Substances) peers

MGTX vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap.

P/S vs peers
12.87 / 5.21 med
+147% premium
Net margin vs peers
-140.3% / 6.3% med
below median
1–14 of 14
AMGNAmgen$182.1B23.624.9621.0%-1.27%
GILDGilead Sciences$153.5B18.045.2128.9%-1.46%
RVMDRevolution Medicines, Inc.$34.6B-30.62+3.14%
BIIBBiogen$29.0B22.442.9313.1%-1.15%
MRNAModerna$25.4B-8.99+3.22%
NBIXNeurocrine Biosciences Inc$15.9B33.245.5616.7%-0.48%
EXELExelixis, Inc.$13.1B16.685.6233.7%-1.04%
KRYSKrystal Biotech, Inc.$10.2B50.0226.3352.6%+1.68%
TECHBio-Techne$9.1B123.617.446.0%+5.36%
HALOHalozyme Therapeutics, Inc.$8.1B25.675.8222.7%-0.03%
IBRXImmunitybio, Inc.$7.7B-21.87+5.01%
RGENRepligen Corp$7.4B152.2710.086.6%-1.20%
KYMRKymera Therapeutics, Inc.$7.4B23.88+0.44%
PCVXVaxcyte, Inc.$7.4B-9688.00+1.57%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.